ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences
June 03 2010 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq:
IMGN) announced today that Daniel Junius, President and CEO, will
present at two investor conferences next week. These presentations
will be webcast live and can be accessed through the “Investor
Information” section of the Company’s website, www.immunogen.com.
An archive of these webcasts will be available at the same location
until June 18, 2010.
- Morgan Joseph Best Ideas
ConferenceWednesday, June 9, 2010 at 3:00 p.m. ETNew
York, NY
- Jefferies 2010 Global Life
Sciences ConferenceThursday, June 10, 2010 at 4:30
p.m. ETNew York, NY
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s potent cell-killing agents
specifically to tumor targets. In addition to the Company’s product
pipeline, compounds utilizing the TAP technology are in clinical
testing through ImmunoGen’s collaborations with Genentech (a wholly
owned member of the Roche Group), sanofi-aventis, Biogen Idec and
Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in
Phase III testing being conducted by Genentech/Roche. Other
ImmunoGen collaborative partners include Bayer Schering Pharma and
Amgen. More information about ImmunoGen can be found at
www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024